麻豆传媒

Dose-limiting toxicity has been linked with worse outcomes specifically in this population

Two trials show positive outcomes

A third as many clinical events versus adjuvant therapy, 6 weeks of treatment for many patients

Adjuvant chemo de-escalation based on ctDNA had no effect on recurrence-free survival

Three new trials address CRC liver metastases

Current option for rare tumor requires a REMS to monitor for drug-induced liver injury

Clear cell histology "is what yields the super response we see in these trials," expert suggests

Anticholinergic oxybutynin for patients taking ADT also improved quality of life in the process

Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group

Improvement also observed in complete remission rates with FLOT over CROSS regimen

PFS was not significantly different for those who skipped lymphadenectomy

Benefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant

Trastuzumab deruxtecan extended its superiority versus chemotherapy into HER2-ultralow

Frontline treatment with mitazalimab plus mFOLFIRINOX achieved responses in 40% of patients